McKesson (NYSE:MCK) Issues FY25 Earnings Guidance

McKesson (NYSE:MCK) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided EPS guidance of $31.25-$32.05 for the period, compared to the consensus EPS estimate of $31.09. The company issued revenue guidance of $355.35-$361.53 billion, compared to the consensus revenue estimate of $341.05 billion.

Analyst Upgrades and Downgrades

MCK has been the subject of several recent analyst reports. Robert W. Baird upped their price objective on shares of McKesson from $603.00 to $671.00 and gave the company an outperform rating in a research note on Wednesday. Citigroup upped their price target on McKesson from $575.00 to $620.00 and gave the company a buy rating in a research report on Tuesday, April 30th. TD Cowen lifted their price objective on McKesson from $563.00 to $652.00 and gave the stock a buy rating in a research report on Wednesday. StockNews.com upgraded McKesson from a buy rating to a strong-buy rating in a report on Saturday. Finally, Evercore ISI lifted their price target on shares of McKesson from $590.00 to $600.00 and gave the company an outperform rating in a report on Wednesday. Two equities research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, McKesson presently has a consensus rating of Moderate Buy and a consensus price target of $569.86.

McKesson Price Performance

NYSE MCK traded down $2.53 during trading hours on Wednesday, reaching $543.22. 1,378,614 shares of the company’s stock traded hands, compared to its average volume of 713,234. The firm has a market cap of $71.38 billion, a PE ratio of 24.61, a PEG ratio of 1.41 and a beta of 0.45. McKesson has a 52-week low of $373.28 and a 52-week high of $566.01. The firm has a 50-day simple moving average of $531.17 and a 200 day simple moving average of $493.81.

McKesson (NYSE:MCK) last released its earnings results on Tuesday, May 7th. The company reported $6.18 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.34 by ($0.16). The business had revenue of $76.36 billion for the quarter, compared to analysts’ expectations of $79.32 billion. McKesson had a net margin of 0.99% and a negative return on equity of 262.63%. McKesson’s revenue for the quarter was up 10.8% on a year-over-year basis. During the same quarter in the previous year, the business posted $7.19 earnings per share. Sell-side analysts forecast that McKesson will post 27.59 EPS for the current fiscal year.

McKesson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, July 1st. Stockholders of record on Monday, June 3rd will be issued a dividend of $0.62 per share. The ex-dividend date is Friday, May 31st. This represents a $2.48 annualized dividend and a dividend yield of 0.46%. McKesson’s payout ratio is presently 11.24%.

Insider Buying and Selling

In other news, EVP Leann B. Smith sold 186 shares of the stock in a transaction that occurred on Tuesday, February 13th. The shares were sold at an average price of $496.00, for a total transaction of $92,256.00. Following the sale, the executive vice president now owns 1,511 shares in the company, valued at $749,456. The transaction was disclosed in a filing with the SEC, which is available at this link. In other news, EVP Leann B. Smith sold 186 shares of the company’s stock in a transaction on Tuesday, February 13th. The stock was sold at an average price of $496.00, for a total transaction of $92,256.00. Following the transaction, the executive vice president now directly owns 1,511 shares of the company’s stock, valued at $749,456. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO Brian S. Tyler sold 3,473 shares of the business’s stock in a transaction dated Friday, March 15th. The stock was sold at an average price of $524.55, for a total value of $1,821,762.15. Following the completion of the transaction, the chief executive officer now directly owns 43,445 shares of the company’s stock, valued at approximately $22,789,074.75. The disclosure for this sale can be found here. 0.21% of the stock is currently owned by company insiders.

McKesson Company Profile

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International. The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products.